242 related articles for article (PubMed ID: 24603504)
1. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
2. Association of disease activity and anti-rheumatic treatment in juvenile idiopathic arthritis with serum lipid profiles: a prospective study.
Shen CC; Yao TC; Yeh KW; Huang JL
Semin Arthritis Rheum; 2013 Jun; 42(6):590-6. PubMed ID: 23290689
[TBL] [Abstract][Full Text] [Related]
3. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
Windschall D; Müller T; Becker I; Horneff G
Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: a case report.
Chen YC; Wang PW; Pan TL; Bazylak G; Shen JJ
Comb Chem High Throughput Screen; 2010 Jul; 13(6):469-81. PubMed ID: 20402637
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Sušić G; Lazarević D; Milošević V; Cvetković M; Pavlović D
Clin Rheumatol; 2019 Jan; 38(1):117-124. PubMed ID: 30128913
[TBL] [Abstract][Full Text] [Related]
13. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Navarro-Millán I; Charles-Schoeman C; Yang S; Bathon JM; Bridges SL; Chen L; Cofield SS; Dell'Italia LJ; Moreland LW; O'Dell JR; Paulus HE; Curtis JR
Arthritis Rheum; 2013 Jun; 65(6):1430-8. PubMed ID: 23460074
[TBL] [Abstract][Full Text] [Related]
14. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
16. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
17. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
18. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
Donnithorne KJ; Cron RQ; Beukelman T
J Rheumatol; 2011 Dec; 38(12):2675-81. PubMed ID: 22089470
[TBL] [Abstract][Full Text] [Related]
19. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis.
Simonini G; Giani T; Stagi S; de Martino M; Falcini F
Rheumatology (Oxford); 2005 Jun; 44(6):777-80. PubMed ID: 15741191
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
Geikowski T; Becker I; Horneff G;
Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]